Literature DB >> 32624276

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.

Umang Swami1, Pedro Isaacsson Velho2, Roberto Nussenzveig1, Jonathan Chipman3, Victor Sacristan Santos4, Stephanie Erickson5, Divya Dharmaraj6, Ajjai Shivaram Alva5, Ulka N Vaishampayan6, John Esther1, Andrew W Hahn7, Benjamin Louis Maughan1, Emmanuel S Antonarakis8, Neeraj Agarwal9.   

Abstract

Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that mtSPOP would be associated with improved outcomes to systemic therapy in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC). Retrospective data of newly diagnosed d-mCSPC patients were collected from four institutions. Eligibility criteria included standard androgen deprivation therapy without intensification, and SPOP mutational status (mtSPOP or wild-type SPOP [wtSPOP]) determination by targeted next-generation sequencing from tumor biopsies. A total of 121 men (25 mtSPOP [21%] and 96 wtSPOP [79%]) were included. After adjusting for covariates, mtSPOP was significantly associated with better median progression-free survival (35 vs 13 mo; adjusted hazard ratio [HR] 0.47; p =  0.016) and overall survival (97 vs 69 mo; adjusted HR 0.32; p =  0.027), with similar HR and p value on the univariate analysis. These findings, upon external validation, may assist with counseling and prognostication in the clinic, and inform the design of future clinical trials in this setting. PATIENT
SUMMARY: : Presence of tumor mutation in speckle-type pox virus and zinc finger protein (SPOP) gene was associated with improved survival outcomes in men with de novo metastatic castration-sensitive prostate cancer receiving standard androgen deprivation therapy.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androgen deprivation therapy; Metastatic hormone-sensitive prostate cancer; Overall survival; Progression-free survival; SPOP

Mesh:

Substances:

Year:  2020        PMID: 32624276      PMCID: PMC7572891          DOI: 10.1016/j.eururo.2020.06.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

Review 1.  The Genomics of Prostate Cancer: emerging understanding with technologic advances.

Authors:  Mark A Rubin; Francesca Demichelis
Journal:  Mod Pathol       Date:  2018-01       Impact factor: 7.842

2.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

3.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

Authors:  Chuandong Geng; Kimal Rajapakshe; Shrijal S Shah; John Shou; Vijay Kumar Eedunuri; Christopher Foley; Warren Fiskus; Mahitha Rajendran; Sue Anne Chew; Martin Zimmermann; Richard Bond; Bin He; Cristian Coarfa; Nicholas Mitsiades
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

4.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Authors:  Chuandong Geng; Bin He; Limei Xu; Christopher E Barbieri; Vijay Kumar Eedunuri; Sue Anne Chew; Martin Zimmermann; Richard Bond; John Shou; Chao Li; Mirjam Blattner; David M Lonard; Francesca Demichelis; Cristian Coarfa; Mark A Rubin; Pengbo Zhou; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-04       Impact factor: 11.205

5.  BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.

Authors:  Jeong Eun Kwon; Muhnho La; Kyu Hee Oh; Young Mi Oh; Gi Ryang Kim; Jae Hong Seol; Sung Hee Baek; Tomoki Chiba; Keiji Tanaka; Ok Sun Bang; Cheol O Joe; Chin Ha Chung
Journal:  J Biol Chem       Date:  2006-03-08       Impact factor: 5.157

6.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

7.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

8.  Genomic correlates of clinical outcome in advanced prostate cancer.

Authors:  Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

Review 9.  Functional roles of Speckle-Type Poz (SPOP) Protein in Genomic stability.

Authors:  Xi Wei; Joshua Fried; Ying Li; Linfei Hu; Ming Gao; Sheng Zhang; Bo Xu
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

Review 10.  The emerging role of SPOP protein in tumorigenesis and cancer therapy.

Authors:  Yizuo Song; Yichi Xu; Chunyu Pan; Linzhi Yan; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Cancer       Date:  2020-01-04       Impact factor: 27.401

View more
  13 in total

1.  Clinical and genomic features of SPOP-mutant prostate cancer.

Authors:  Mari Nakazawa; Mike Fang; Catherine H Marshall; Tamara L Lotan; Pedro Isaacsson Velho; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2021-11-15       Impact factor: 4.104

Review 2.  Genomic biomarkers to guide precision radiotherapy in prostate cancer.

Authors:  Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran
Journal:  Prostate       Date:  2022-08       Impact factor: 4.012

Review 3.  Genomic Profiling of Prostate Cancer: An Updated Review.

Authors:  Koji Hatano; Norio Nonomura
Journal:  World J Mens Health       Date:  2021-07-14       Impact factor: 6.494

4.  GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.

Authors:  Marieke Burleson; Janice J Deng; Tai Qin; Thu Minh Duong; Yuqian Yan; Xiang Gu; Debodipta Das; Acarizia Easley; Michael A Liss; P Renee Yew; Roble Bedolla; Addanki Pratap Kumar; Tim Hui-Ming Huang; Yi Zou; Yidong Chen; Chun-Liang Chen; Haojie Huang; Lu-Zhe Sun; Thomas G Boyer
Journal:  Mol Cancer Res       Date:  2021-10-05       Impact factor: 6.333

5.  Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.

Authors:  Fadi Taza; Albert E Holler; Wei Fu; Hao Wang; Nabil Adra; Costantine Albany; Ryan Ashkar; Heather H Cheng; Alexandra O Sokolova; Neeraj Agarwal; Adam Kessel; Alan Bryce; Nellie Nafissi; Pedro Barata; A Oliver Sartor; Diogo Bastos; Oren Smaletz; Jacob E Berchuck; Mary-Ellen Taplin; Rahul Aggarwal; Cora N Sternberg; Panagiotis J Vlachostergios; Ajjai S Alva; Christopher Su; Catherine H Marshall; Emmanuel S Antonarakis
Journal:  JCO Precis Oncol       Date:  2021-07-22

6.  Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Juan Briones; Maira Khan; Amanjot K Sidhu; Liying Zhang; Martin Smoragiewicz; Urban Emmenegger
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

Review 7.  Clinical implications of genomic alterations in metastatic prostate cancer.

Authors:  Takayuki Sumiyoshi; Kim N Chi; Alexander W Wyatt
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-01-15       Impact factor: 5.455

8.  Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model.

Authors:  Yanlong Zhang; Ruiqiao Zhang; Fangzhi Liang; Liyun Zhang; Xuezhi Liang
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

9.  Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.

Authors:  Andrew J Armstrong; Xiaotong Li; Matthew Tucker; Shantao Li; Xinmeng Jasmine Mu; Kenneth Wha Eng; Andrea Sboner; Mark Rubin; Mark Gerstein
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-10       Impact factor: 5.554

10.  The tumor microenvironment and immune responses in prostate cancer patients.

Authors:  J T W Kwon; R J Bryant; E E Parkes
Journal:  Endocr Relat Cancer       Date:  2021-07-15       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.